

# Jon H Chung

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7432691/publications.pdf>

Version: 2024-02-01

128  
papers

3,353  
citations

159585

30  
h-index

161849

54  
g-index

129  
all docs

129  
docs citations

129  
times ranked

5941  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2022, 28, 728-737.	7.0	20
2	Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 48-53.	6.3	30
3	Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms. <i>Clinical Cancer Research</i> , 2021, 27, 3094-3105.	7.0	101
4	Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer to identify targetable BRCA alterations and AR resistance mechanisms.. <i>Journal of Clinical Oncology</i> , 2021, 39, 25-25.	1.6	2
5	Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 367.e1-367.e5.	1.6	11
6	Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors. <i>Translational Oncology</i> , 2021, 14, 101184.	3.7	13
7	Comprehensive genomic profiling of histologic subtypes of urethral carcinomas. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 731.e1-731.e15.	1.6	7
8	Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. <i>European Urology Focus</i> , 2021, 7, 1339-1346.	3.1	58
9	Genomic Characterization of Testicular Germ Cell Tumors Relapsing After Chemotherapy. <i>European Urology Focus</i> , 2020, 6, 122-130.	3.1	30
10	The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. <i>Oncologist</i> , 2020, 25, e39-e47.	3.7	13
11	Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. <i>European Urology</i> , 2020, 77, 439-446.	1.9	228
12	Squamous Transformation of Prostate Adenocarcinoma: A Report of Two Cases With Genomic Profiling. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e289-e292.	1.9	7
13	Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. <i>European Urology</i> , 2020, 77, 636-643.	1.9	75
14	Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5974-5989.	7.0	87
15	Targetable gene fusions and aberrations in genitourinary oncology. <i>Nature Reviews Urology</i> , 2020, 17, 613-625.	3.8	35
16	Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling. <i>Lung Cancer</i> , 2020, 148, 69-78.	2.0	25
17	Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. <i>JCO Precision Oncology</i> , 2020, 4, 442-465.	3.0	103
18	Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e543-e556.	1.9	22

#	ARTICLE	IF	CITATIONS
19	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. <i>European Urology</i> , 2020, 77, 548-556.	1.9	41
20	Urothelial cancer harbours <i>EGFR</i> and <i>HER2</i> amplifications and exon 20 insertions. <i>BJU International</i> , 2020, 125, 739-746.	2.5	14
21	Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5527-5527.	1.6	3
22	Comprehensive genomic profiling (CGP) in post-systemic treatment (Post) metastatic sites (MET) and pretreatment (Pre) primary tumors (PT) of metastatic prostate cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 175-175.	1.6	1
23	Pan-tumor analyses of kinase fusions detected in circulating tumor DNA (ctDNA) and concordance with paired tissue.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3517-3517.	1.6	0
24	Patient-matched tissue and liquid biopsies identify shared and acquired genomic alterations in breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1050-1050.	1.6	15
25	Acquired RB1 mutations in estrogen receptor-positive (ER+) clinically advanced and metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1053-1053.	1.6	0
26	Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3558-3558.	1.6	1
27	Comprehensive genomic profiling (CGP) of histologic subtypes of urethral carcinomas (UrthCa).. <i>Journal of Clinical Oncology</i> , 2020, 38, 426-426.	1.6	0
28	The emerging target <i>KRAS</i> G12C in genitourinary malignancies.. <i>Journal of Clinical Oncology</i> , 2020, 38, 434-434.	1.6	1
29	<i>NF2</i> mutation-driven renal cell carcinomas (RCC): A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 726-726.	1.6	6
30	Metastatic renal cell carcinoma (mRCC) in young patients: A comprehensive genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 727-727.	1.6	0
31	Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors. <i>European Urology Focus</i> , 2019, 5, 748-755.	3.1	29
32	Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 831-840.	1.4	31
33	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. <i>JCO Precision Oncology</i> , 2019, 3, 1-23.	3.0	63
34	Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. <i>Gastroenterology</i> , 2019, 156, 2242-2253.e4.	1.3	224
35	Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. <i>Oncologist</i> , 2019, 24, 791-797.	3.7	36
36	Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart. <i>Oncologist</i> , 2019, 24, e142-e145.	3.7	22

#	ARTICLE	IF	CITATIONS
37	Pan-Cancer Analysis of <i>CDK12</i> Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype. <i>Oncologist</i> , 2019, 24, 1526-1533.	3.7	39
38	An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis. <i>European Urology</i> , 2019, 75, 201-203.	1.9	54
39	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 255-264.	1.1	53
40	Immunotherapy predictive biomarkers in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1023-1023.	1.6	2
41	Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4087-4087.	1.6	42
42	Adenocarcinoma (ACB), urothelial carcinoma (UCB) and squamous cell carcinoma (SCCB) of the bladder: A Comprehensive Genomic Profiling (CGP) Study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4533-4533.	1.6	1
43	Comprehensive genomic profiling (CGP) of upper-tract (UTUC) and bladder (BUC) urothelial carcinoma reveals opportunities for therapeutic and biomarker development.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4581-4581.	1.6	6
44	Metastatic penile (mPSCC), uterine cervical (mCSCC), and skin (mSSCC) squamous cell carcinomas: A comparative genomic profiling (CGP) study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4585-4585.	1.6	1
45	MSI-H testing via hybrid capture based NGS sequencing of liquid biopsy samples.. <i>Journal of Clinical Oncology</i> , 2019, 37, 504-504.	1.6	19
46	Penile and uterine cervical squamous cell carcinomas: A comparative genomic profiling study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 514-514.	1.6	2
47	Genomic features of metastatic testicular sex cord stromal tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 532-532.	1.6	1
48	Anal melanoma: A comparative comprehensive genomic profiling study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 551-551.	1.6	1
49	Analysis of EGFR mutant upper tract and bladder urothelial carcinoma (UC) reveals distinct mutational landscape.. <i>Journal of Clinical Oncology</i> , 2019, 37, 416-416.	1.6	0
50	Ductal and acinar carcinomas of the prostate: A comparative comprehensive genomic profiling study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 271-271.	1.6	0
51	Genomic findings in adenocarcinoma of the urinary bladder.. <i>Journal of Clinical Oncology</i> , 2019, 37, 132-132.	1.6	0
52	Malignant pheochromocytoma: A comprehensive genomic profiling study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 508-508.	1.6	2
53	First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 391-391.	1.6	1
54	Analysis of HER2 mutant bladder urothelial carcinomas reveals unique mutational signature.. <i>Journal of Clinical Oncology</i> , 2019, 37, 460-460.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets.. Journal of Clinical Oncology, 2019, 37, 4535-4535.	1.6	0
56	Towards the noninvasive identification of pathologic responders to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC).. Journal of Clinical Oncology, 2019, 37, 4540-4540.	1.6	0
57	Analysis of <i>EGFR</i> mutant urothelial carcinoma (UC) reveals distinct mutational landscape.. Journal of Clinical Oncology, 2019, 37, 4545-4545.	1.6	0
58	Malignant pheochromocytoma (MP): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2019, 37, 4584-4584.	1.6	0
59	Extra-mammary Paget's disease (EMPD) of the skin: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2019, 37, 9591-9591.	1.6	1
60	Anal melanoma: A comparative comprehensive genomic profiling study.. Journal of Clinical Oncology, 2019, 37, 9566-9566.	1.6	0
61	Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Annals of Oncology, 2018, 29, 872-880.	1.2	73
62	Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clinical Cancer Research, 2018, 24, 1881-1890.	7.0	59
63	BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. Clinical Breast Cancer, 2018, 18, 184-188.	2.4	34
64	Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. European Journal of Cancer, 2018, 96, 128-130.	2.8	9
65	<i>BRAF</i> in Lung Cancers: Analysis of Patient Cases Reveals Recurrent <i>BRAF</i> Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. JCO Precision Oncology, 2018, 2, 1-15.	3.0	24
66	Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study. JCO Precision Oncology, 2018, 2, 1-12.	3.0	3
67	Large-Cell Neuroendocrine Carcinoma of the Lung: A Focused Analysis of <i>BRAF</i> Alterations and Case Report of a <i>BRAF</i> Non-V600 Mutated Tumor Responding to Targeted Therapy. JCO Precision Oncology, 2018, 2, 1-12.	3.0	6
68	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. Journal of Clinical Oncology, 2018, 36, 3353-3360.	1.6	474
69	RET rearrangements are actionable alterations in breast cancer. Nature Communications, 2018, 9, 4821.	12.8	87
70	Analytical Validation of a Hybrid Capture-Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA. Journal of Molecular Diagnostics, 2018, 20, 686-702.	2.8	149
71	Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. European Urology, 2018, 74, 124-128.	1.9	52
72	Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. European Urology, 2018, 73, 71-78.	1.9	87

#	ARTICLE	IF	CITATIONS
73	Primary pulmonary sarcomas (PSRC): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, 11553-11553.	1.6	1
74	Frequency of genomic biomarkers of response to immunotherapy in sarcoma.. Journal of Clinical Oncology, 2018, 36, 11579-11579.	1.6	5
75	<i>PBRM1</i> mutation and immunotherapy efficacy: A comprehensive genomic profiling (CGP) assessment.. Journal of Clinical Oncology, 2018, 36, 12091-12091.	1.6	4
76	MSI-high and MSI-stable colorectal carcinomas (CRC): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, 3574-3574.	1.6	5
77	Preoperative pembrolizumab (pembro) before radical cystectomy (RC) for muscle-invasive urothelial bladder carcinoma (MIUC): Interim clinical and biomarker findings from the phase 2 PURE-01 study.. Journal of Clinical Oncology, 2018, 36, 4507-4507.	1.6	15
78	Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage.. Journal of Clinical Oncology, 2018, 36, 4547-4547.	1.6	6
79	Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors (TGCT).. Journal of Clinical Oncology, 2018, 36, 4555-4555.	1.6	1
80	PBRM1 genomic alterations in mesothelioma: Potential predictor of immunotherapy efficacy.. Journal of Clinical Oncology, 2018, 36, 8562-8562.	1.6	2
81	Comprehensive genomic profiling to identify recurrent kinase fusions in pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, 292-292.	1.6	1
82	Comprehensive genomic profiling of ctDNA in patients with colon cancer and its fidelity to the genomics of the tumor biopsy.. Journal of Clinical Oncology, 2018, 36, 569-569.	1.6	4
83	Difference of genomic signatures and opportunities for targeted and immunotherapies in castrate resistant TMPRSS2:ERG fusion positive and TMPRSS2:ERG wild type refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).. Journal of Clinical Oncology, 2018, 36, 348-348.	1.6	4
84	Correlation of circulating tumor DNA (ctDNA) assessment with tissue-based comprehensive genomic profiling (CGP) in metastatic urothelial cancer (mUC).. Journal of Clinical Oncology, 2018, 36, 453-453.	1.6	2
85	Refractory testicular pure seminoma (PS) and non-seminomatous(NS) germ cell tumors (GCT): A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, 565-565.	1.6	1
86	Comparison of tumor mutational burden (TMB) in PBRM1/BAP1-based subsets of advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2018, 36, 634-634.	1.6	1
87	Comparative genomic profiling (CGP) of refractory/metastatic penile (mPSCC) and non-penile cutaneous squamous cell carcinoma (mCSCC).. Journal of Clinical Oncology, 2018, 36, 552-552.	1.6	1
88	Choroid plexus tumors of the central nervous system: Searching for therapy targets with comprehensive genomic profiling.. Journal of Clinical Oncology, 2018, 36, e14084-e14084.	1.6	0
89	PD-L1 genomic alterations (GA) in solid tumors and hematologic malignancies: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, 12092-12092.	1.6	0
90	<i>FGFR3</i> Driven Metastatic Urothelial Carcinoma of the Urinary Bladder (mUCB): A Comprehensive Genomic Profiling Study.. Journal of Clinical Oncology, 2018, 36, 4531-4531.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Genomic subtypes of angiosarcoma: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, 11576-11576.	1.6	1
92	Carcinomas of the renal medulla: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, e16586-e16586.	1.6	0
93	Comprehensive genomic profiling of metastatic cutaneous adnexal carcinomas to reveal multiple routes to targeted and immunotherapies.. Journal of Clinical Oncology, 2018, 36, 9587-9587.	1.6	1
94	PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC).. Journal of Clinical Oncology, 2018, 36, TPS4595-TPS4595.	1.6	1
95	Primary sarcomas of the urinary bladder: A comprehensive genomic profiling (CGP) study.. Journal of Clinical Oncology, 2018, 36, e16530-e16530.	1.6	0
96	Landscape of kinase rearrangements (kRE) detected in circulating tumor DNA (ctDNA).. Journal of Clinical Oncology, 2018, 36, 12041-12041.	1.6	0
97	Differences in genomic signatures and opportunities for targeted and immunotherapy treatment between castrate-resistant <i>TPRSS2:ERG</i> fusion-positive and -negative refractory acinar (CRPC) and neuroendocrine prostate cancer (CRNEPC).. Journal of Clinical Oncology, 2018, 36, 5061-5061.	1.6	0
98	Comprehensive genomic profiling of malignant phyllodes tumors of the breast. Breast Cancer Research and Treatment, 2017, 162, 597-602.	2.5	38
99	HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib. Journal of Thoracic Oncology, 2017, 12, 446-457.	1.1	75
100	Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. Annals of Oncology, 2017, 28, 2866-2873.	1.2	67
101	Exceptional Response to Palbociclib in Metastatic Collecting Duct Carcinoma Bearing a CDKN2A Homozygous Deletion. JCO Precision Oncology, 2017, 1, 1-5.	3.0	11
102	Biallelic Deletion of PALB2 Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition. JCO Precision Oncology, 2017, 1, 1-7.	3.0	3
103	BRAF: An emerging target for triple-negative breast cancer.. Journal of Clinical Oncology, 2017, 35, 1099-1099.	1.6	7
104	Genomic profiling of squamous malignancies across anatomic sites.. Journal of Clinical Oncology, 2017, 35, 11512-11512.	1.6	2
105	Molecular landscape of BRAF mutations in large cell neuroendocrine carcinoma of lung: An analysis of BRAF mutations and a case report of a BRAF non-V600E mutated tumor responding to targeted therapy.. Journal of Clinical Oncology, 2017, 35, 11621-11621.	1.6	2
106	Precision medicine for gallbladder cancer using somatic copy number amplifications (SCNA) and DNA repair pathway gene alterations.. Journal of Clinical Oncology, 2017, 35, 4076-4076.	1.6	8
107	Comprehensive genomic profiling (CGP) of advanced papillary renal cell carcinoma (PRCC) to reveal distinctions from TCGA dataset.. Journal of Clinical Oncology, 2017, 35, 4517-4517.	1.6	3
108	BRCA1/2 reversion mutations revealed in breast and gynecologic cancers sequenced during routine clinical care using tissue or liquid biopsy.. Journal of Clinical Oncology, 2017, 35, 5551-5551.	1.6	2

#	ARTICLE	IF	CITATIONS
109	Comprehensive genomic profiling of parathyroid carcinoma.. Journal of Clinical Oncology, 2017, 35, 6088-6088.	1.6	1
110	Genomic alterations (GA) and tumor mutational burden (TMB) in large cell neuroendocrine carcinoma of lung (L-LCNEC) as compared to small cell lung carcinoma (SCLC) as assessed via comprehensive genomic profiling (CGP).. Journal of Clinical Oncology, 2017, 35, 8517-8517.	1.6	11
111	Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 9025-9025.	1.6	1
112	<i>BRAF</i> fusions in clinically advanced non-small cell lung cancer: An emerging target for anti- <i>BRAF</i> therapies.. Journal of Clinical Oncology, 2017, 35, 9072-9072.	1.6	11
113	Identification of Targetable <i>ALK</i> Rearrangements in Pancreatic Ductal Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 555-562.	4.9	79
114	Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with pancreatic ductal adenocarcinoma (PDA).. Journal of Clinical Oncology, 2017, 35, 4128-4128.	1.6	0
115	BRCA1/2 reversion mutations in pancreatobiliary cancer identified from patient biopsies.. Journal of Clinical Oncology, 2017, 35, 4130-4130.	1.6	0
116	Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).. Journal of Clinical Oncology, 2017, 35, 1016-1016.	1.6	1
117	<i>BRCA1/2</i> reversion mutations in prostate cancer identified from clinical tissue and liquid biopsy samples.. Journal of Clinical Oncology, 2017, 35, 5024-5024.	1.6	1
118	Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. Annals of Oncology, 2016, 27, 1336-1341.	1.2	78
119	A Combination of Targeted Therapy with Chemotherapy Backbone Induces Response in a Treatment-Resistant Triple-Negative MCL1-Amplified Metastatic Breast Cancer Patient. Case Reports in Oncology, 2016, 9, 112-118.	0.7	4
120	Repurposing the Antihelminthic Mebendazole as a Hedgehog Inhibitor. Molecular Cancer Therapeutics, 2015, 14, 3-13.	4.1	78
121	Predictive and Prognostic Significance of Comprehensive Genomic Profiling in Patients with Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 2651-2651.	1.4	0
122	A PTCH1 Homolog Transcriptionally Activated by p53 Suppresses Hedgehog Signaling. Journal of Biological Chemistry, 2014, 289, 33020-33031.	3.4	29
123	A Poorly Differentiated Malignant Neoplasm Lacking Lung Markers Harbors an EML4-ALK Rearrangement and Responds to Crizotinib. Case Reports in Oncology, 2014, 7, 628-632.	0.7	13
124	A loss-of-function mutation in PTCH1 suggests a role for autocrine hedgehog signaling in colorectal tumorigenesis. Oncotarget, 2013, 4, 2208-2211.	1.8	28
125	Targeted Mutations in the ATR Pathway Define Agent-Specific Requirements for Cancer Cell Growth and Survival. Molecular Cancer Therapeutics, 2012, 11, 98-107.	4.1	8
126	Chk1 suppresses bypass of mitosis and tetraploidization in p53-deficient cancer cells. Cell Cycle, 2012, 11, 1564-1572.	2.6	16



#	ARTICLE	IF	CITATIONS
127	Cdk2 Is Required for p53-Independent G2/M Checkpoint Control. PLoS Genetics, 2010, 6, e1000863.	3.5	80
128	Checkpoint bypass and cell viability. Cell Cycle, 2010, 9, 2102-2107.	2.6	4